S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
S&P 500   5,149.42
DOW   38,790.43
QQQ   437.48
3 Large-Cap Stocks Buying Back Shares Aggressively
Semis, Nvidia Set for Big Moves as GTC Conference Kicks Off
Here’s Why Bitcoin Miners Stopped Rising With Bitcoin Prices
2 Deep Value, High Yield Stocks With a Double-Digit Upside
3 Stocks About to Boom on Unusual Call Option Volume
How major US stock indexes fared Monday, 3/18/2024
Oil Prices Up Again, Should You Buy This Time?
NASDAQ:BIVI

BioVie (BIVI) Stock Price, News & Analysis

$0.65
-0.06 (-8.49%)
(As of 03/18/2024 ET)
Today's Range
$0.64
$0.71
50-Day Range
$0.65
$1.89
52-Week Range
$0.64
$10.28
Volume
1.61 million shs
Average Volume
2.72 million shs
Market Capitalization
$25.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

BioVie MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,137.8% Upside
$8.00 Price Target
Short Interest
Healthy
2.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of BioVie in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.52 out of 5 stars

Medical Sector

746th out of 947 stocks

Pharmaceutical Preparations Industry

349th out of 435 stocks

BIVI stock logo

About BioVie Stock (NASDAQ:BIVI)

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

BIVI Stock Price History

BIVI Stock News Headlines

The AI Bottleneck No One is Talking About
Renewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.
BIVI Oct 2024 1.500 put
BIVI Jul 2024 3.500 put
BIVI Apr 2024 5.000 put
They said crypto was dead. It went up 100X.
Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.
BioVie Inc. Announces Closing of Public Offering
BIVI Apr 2024 1.500 put
BIVI Oct 2024 0.500 put
Why BioVie (BIVI) Shares Are Down 40%
Why Is BioVie (BIVI) Stock Down 41% Today?
See More Headlines
Receive BIVI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/18/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BIVI
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$11.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+1,137.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-50,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.42 per share

Miscellaneous

Free Float
38,009,000
Market Cap
$25.80 million
Optionable
Optionable
Beta
0.90
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Cuong Viet Do M.B.A. (Age 58)
    President, CEO & Director
    Comp: $1.08M
  • Ms. Joanne Wendy Kim CPA (Age 69)
    CFO, Treasurer & Corporate Secretary
    Comp: $397.38k
  • Dr. Joseph M. Palumbo M.D. (Age 64)
    Executive VP of R&D and Chief Medical Officer
    Comp: $722k
  • Mr. Clarence N. Ahlem (Age 69)
    Senior Vice President of Operations
  • Dr. Penelope Markham Ph.D. (Age 58)
    Senior Vice President of Liver Disease Program
  • Ms. Denise Smith
    Senior Vice President of Manufacturing & Development
  • Dr. Christopher L. Reading Ph.D. (Age 76)
    Senior Vice President of Alzheimer's Disease Program
  • Ms. Sarah Overton Hoit (Age 56)
    Chief Social Impact Officer

BIVI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioVie stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioVie in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BIVI shares.
View BIVI analyst ratings
or view top-rated stocks.

What is BioVie's stock price target for 2024?

2 equities research analysts have issued 1-year target prices for BioVie's shares. Their BIVI share price targets range from $5.00 to $11.00. On average, they predict the company's share price to reach $8.00 in the next year. This suggests a possible upside of 1,137.8% from the stock's current price.
View analysts price targets for BIVI
or view top-rated stocks among Wall Street analysts.

How have BIVI shares performed in 2024?

BioVie's stock was trading at $1.26 at the beginning of the year. Since then, BIVI stock has decreased by 48.7% and is now trading at $0.6463.
View the best growth stocks for 2024 here
.

When is BioVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our BIVI earnings forecast
.

How were BioVie's earnings last quarter?

BioVie Inc. (NASDAQ:BIVI) posted its quarterly earnings results on Monday, February, 12th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.10.

Who are BioVie's major shareholders?

BioVie's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.93%), Vanguard Group Inc. (0.88%), Northern Trust Corp (0.29%), Charles Schwab Investment Management Inc. (0.08%), Virtu Financial LLC (0.06%) and Envestnet Asset Management Inc. (0.06%). Insiders that own company stock include Cuong V Do, Joanne Wendy Kim, Richard J Berman and Steve Gorlin.
View institutional ownership trends
.

How do I buy shares of BioVie?

Shares of BIVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIVI) was last updated on 3/19/2024 by MarketBeat.com Staff

From Our Partners